ARTICLE | Clinical News
IONIS-FXIRx: Ph II data
December 1, 2016 11:41 AM UTC
A double-blind, Canadian Phase II trial in 43 patients with ESRD receiving hemodialysis showed that 200 and 300 mg doses of subcutaneous IONIS-FXIRx dosed twice weekly for 2 weeks and then once weekly...
BCIQ Target Profiles